|
| 1 |
|
Conditions listed in this trial |
|
|
Breast Cancer |
|
| 2 |
|
Additional conditions recognized in this trial |
|
|
Breast Neoplasms |
|
|
Carcinoma |
|
|
Carcinoma in Situ |
|
|
Carcinoma, Ductal |
|
|
Carcinoma, Ductal, Breast |
|
|
Carcinoma, Intraductal, Noninfiltrating |
|
| 3 |
|
More general conditions related to this trial |
|
|
Adenocarcinoma |
|
|
Breast Diseases |
|
|
Neoplasms |
|
|
Neoplasms by Histologic Type |
|
|
Neoplasms by Site |
|
|
Neoplasms, Ductal, Lobular, and Medullary |
|
|
Neoplasms, Glandular and Epithelial |
|
|
Skin Diseases |
|
| 4 |
|
Interventions listed in this trial |
|
|
anastrozole |
|
|
tamoxifen citrate |
|
|
adjuvant therapy |
|
|
radiation therapy |
|
| 5 |
|
Additional drug interventions recognized in this trial |
|
|
Tamoxifen |
|
| 6 |
|
More general drug interventions related to this trial |
|
|
Antineoplastic Agents |
|
|
Antineoplastic Agents, Hormonal |
|
|
Aromatase Inhibitors |
|
|
Bone Density Conservation Agents |
|
|
Enzyme Inhibitors |
|
|
Estrogen Antagonists |
|
|
Estrogen Receptor Modulators |
|
|
Hormone Antagonists |
|
|
Hormones, Hormone Substitutes, and Hormone Antagonists |
|
|
Molecular Mechanisms of Pharmacological Action |
|
|
Pharmacologic Actions |
|
|
Physiological Effects of Drugs |
|
|
Selective Estrogen Receptor Modulators |
|
|
Therapeutic Uses |
|
| 7 |
|
Sponsors listed in this trial |
|
|
Institute of Cancer Research, United Kingdom |
